Mesoblast's high-risk programs drive inflated valuation. Find out why MESO stock remains a "sell" as execution risks outweigh ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...

Aging is a privilege, but it also brings risks-including an increased likelihood of developing age-related diseases including ...

Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Guerlain continues its legacy of innovation with the latest evolution of its iconic Abeille Royale Youth Watery Oil Serum.

Aging is a privilege, but it also brings risks-including an increased likelihood of developing age-related diseases including cancer.

Ryoncil ® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute ...

Aging is a privilege, but it also brings risks—including an increased likelihood of developing age-related diseases including ...

Cancer models developed with 3D bioprinting technology allow for rapid evaluation of individual drug responses.

Profiling cells from ovarian endometriosis revealed signaling interactions that may sustain legion growth, highlighting ...